Milestone Targets Sample Clauses

The Milestone Targets clause defines specific objectives or deliverables that must be achieved by certain dates during the course of a project or contract. Typically, it outlines a schedule of key tasks or phases, each with associated deadlines and sometimes linked payments or performance criteria. By clearly setting out these targets, the clause ensures that progress can be measured objectively and helps manage expectations, reducing the risk of delays or misunderstandings between the parties.
Milestone Targets. 8.1 As noted above, ▇▇▇▇▇ ▇▇▇▇ already has a good record on access for under-represented groups and on comprehensive and effective engagement with outreach activities. 8.2 ▇▇▇▇▇ ▇▇▇▇ is concerned that the introduction of fees might act as a deterrent to the above groups to participation in higher education, especially in view of the widespread misunderstandings about fee repayment partly generated by inaccurate media coverage. 8.3 Accordingly, given the already high level of representation in the ▇▇▇▇▇ ▇▇▇▇ student body of under-represented groups, our objective will be to use bursaries, outreach programmes and communication to protect our current levels of access. 8.4 Given our good record we feel that it would not be reasonable to project forward a large increase in the levels of participation by under-represented groups or in outreach activity, although we will always seek opportunities to make positive changes. 8.5 We think that the milestone targets set out in Appendix II are sufficiently stretching in our particular circumstances.
View SourceView Similar (3)
Milestone Targets. Goldsmiths already recruits strongly from state schools and amongst students from backgrounds which are typically under-represented in higher education. As a result we feel it would be appropriate for us to set milestones which aim to consolidate our current levels of recruitment from state schools, from social groups IV-VII and from low participation neighbourhoods. We feel that this is reasonable as these groups are the most vulnerable to any detrimental effects of an increase in fees. We will use our bursaries to offset the threat of economic hardship to students and encourage applications by developing our outreach and widening participation activities. In addition, the College will work with Goldsmiths Students’ Union, to provide support for better levels of retention amongst all students, but particularly widening participation entrants. These milestones are based on HEFCE performance indicators. From State Schools or Colleges 87% 92% Socio-Economic Groups IV-VII 29.3% 25.9% Low Participation Neighbourhoods 6.5% 6.4% Recruitment Target Group 2006-07 2007-08 2008-09 2009-10 2010-11 Entrants from State Schools/ Colleges 90.5% 90.5% 85.2% 85.2% 85.2% Socio-Economic Groups IV-VII 25.5% 25.5% 25.5% 25.5% 25.5% Low Participation Neighbourhoods 9.5% 9.5% 9.5% 9.5% 9.5%
View SourceView Similar (2)

Related to Milestone Targets

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and: (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless: (1) it will suffer significant uncompensated economic or operational harm from the delay, (2) attainment of the same milestone has previously been delayed, or (3) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.

  • Milestone A principal event specified in the Contract Documents including the Material Completion and Occupancy Date and other events relating to an intermediate completion date or time.

  • Sales Milestones On a Co-Co Product-by-Co-Co Product basis, Celgene shall make the following sales milestone payments to Jounce that are set forth below upon the first achievement by or on behalf of Celgene, its Affiliates or Sublicensees of the Sales Milestone Events set forth below with respect to sales of such Co-Co Product in the ROW Territory. [***] [***] [***] [***]

  • Development Milestone Payments TriSalus shall pay (or cause to be paid) to Dynavax, in accordance with and subject to the terms of this Section 2.3, Section 2.4 and Section 6.4 (each such milestone, a “Development Milestone”, and each payment in respect thereof, a “Development Milestone Payment”): (i) Upon the successful completion by a Milestone Obligor after the Closing of a [**] study with respect to a Product using PEDD, a payment of [**] US Dollars ($[**]), with such Development Milestone Payment being payable only once (for purposes of the foregoing, successful completion means completion of such study in accordance with the plan for such study); (ii) For the first patient Dosed by a Milestone Obligor in each Phase 1 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iii) For the first patient Dosed by a Milestone Obligor in each Phase 2 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iv) For each Phase 2 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 2 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 2 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (v) For each Phase 3 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 3 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 3 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (vi) Upon receipt by a Milestone Obligor of each Regulatory Approval for any Product for any Indication in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (vii) Upon receipt by a Milestone Obligor for each Regulatory Approval of any Product for any Indication in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (viii) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vi) for receipt of such Regulatory Approval), regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; and (ix) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vii) for receipt of such Regulatory Approval), regardless ​ of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval.